Latest News

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
12/19/13AcelRx Secures $40 Million Credit Facility with Hercules Technology Growth Capital
REDWOOD CITY, Calif., Dec. 19, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it has entered into a new amended and restated credit facility with Hercules Technology Growth Capital, Inc. (NYSE: HTGC) that extends AcelRx's current relationship with Hercules, which was established in June 2011. The... 
Printer Friendly Version
12/16/13AcelRx and Grunenthal Announce Collaboration for EU Commercialization of ZALVISO™
- FDA establishes the PDUFA action date of July 27, 2014 for Zalviso - - Conference Call Scheduled Monday, December 16th 2013 for 8:30 a.m. Eastern Time - REDWOOD CITY, Calif. and AACHEN, Germany, Dec. 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) and Grunenthal GmbH announced today that they have entered into a commercial collaboration, covering the territory of the European Union, certain other European countries and Australia for ZALVISO™ (previously known as ARX-... 
Printer Friendly Version
12/13/13AcelRx Pharmaceuticals Presents ARX-04 Dose-Finding Phase 2 Study Data at Anesthesia Medical Conference
- 30 mcg sufentanil NanoTab treatment group experienced rapid onset of action with statistically significant pain relief and reduced pain intensity at 30 minutes - REDWOOD CITY, Calif., Dec. 13, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today presented additional detail from the Phase 2 dose-finding study of ARX-0... 
Printer Friendly Version
12/11/13AcelRx Pharmaceuticals Adds New Board Member
REDWOOD CITY, Calif., Dec. 11, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard F. Afable, M.D., president and CEO of Covenant Health Network, was appointed to the company's board of directors.  Guy Nohra, co-founder and managing director of venture capital firm Alta Partners, resigned from the ... 
Printer Friendly Version
12/02/13Zalviso™ New Drug Application Accepted for Filing by FDA
REDWOOD CITY, Calif., Dec. 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the Zalviso™ New Drug Application (NDA) was accepted for filing by the FDA on November 26, 2013. The acceptance for filing of the NDA indicates the FDA has determined that the application is sufficiently complete to permit a ... 
Printer Friendly Version
11/26/13AcelRx Pharmaceuticals to Present at the 25th Annual Piper Jaffray Healthcare Conference
REDWOOD CITY, Calif., Nov. 26, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the 25th Annual Piper Jaffray Healthcare Conference at the New York Palace in New York, NY.  The presentation is scheduled for Wednesday, December 4, 2013... 
Printer Friendly Version
11/05/13AcelRx Pharmaceuticals Reports Third Quarter 2013 Financial Results
REDWOOD CITY, Calif., Nov. 5, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX),  a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and nine months ended September 30, 2013. "With the submission of our NDA at the end of September for Zalviso™, AcelRx has commenced activities related to an anticipated U.S. commercial launch," ... 
Printer Friendly Version
10/22/13AcelRx Pharmaceuticals to Hold Third Quarter 2013 Financial Results Conference Call and Webcast on November 5, 2013
REDWOOD CITY, Calif., Oct. 22, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release third quarter 2013 financial results after market close on Tuesday, November 5, 2013.  AcelRx management will host an investment-community conference call at 4:30 p.m. eastern time (1:30 p.m. pacific time) on... 
Printer Friendly Version
10/15/13AcelRx Pharmaceuticals Announces Data Presentations for Zalviso™ at US and International Medical Meetings
First medical meeting data presentations from Phase 3 clinical trial conducted in orthopedic surgery patients REDWOOD CITY, Calif., Oct. 15, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced presentations of its previously reported Phase 3 data for Zalviso™  (sufentanil sublingual microtablet system) at se... 
Printer Friendly Version
10/08/13AcelRx Pharmaceuticals Provides Update on its Patent Portfolio for Zalviso™ and its Proprietary Platform Technologies
Patent estate includes nine issued U.S. patents, nineteen patents worldwide REDWOOD CITY, Calif., Oct. 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today provided an update regarding its growing patent estate which totals 19 issued patents worldwide.  These issued patents cover AcelRx's sufentanil Nanotab™, medica... 
Printer Friendly Version
09/30/13AcelRx Pharmaceuticals Submits New Drug Application to the FDA for Zalviso™
Zalviso NDA submitted for the management of moderate-to-severe acute pain in adult patients in the hospital setting REDWOOD CITY, Calif., Sept. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for Zalviso™ (s... 
Printer Friendly Version
09/04/13David H. Chung Joins AcelRx Pharmaceuticals as Chief Commercial Officer
REDWOOD CITY, Calif., Sept. 4, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that David H. Chung has joined the company as chief commercial officer effective September 2, 2013.  Mr. Chung brings over 20 years of hospital-focused, global medical device and pharmaceutical sales and marketing experience, mos... 
Printer Friendly Version
08/30/13AcelRx Pharmaceuticals to Present at the Stifel Healthcare Conference 2013
REDWOOD CITY, Calif., Aug. 30, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the Stifel Healthcare Conference 2013 at the Four Seasons Hotel in Boston, MA.  The presentation is scheduled for Wednesday, September 11, 2013 at 9:45 a.... 
Printer Friendly Version
08/12/13AcelRx Pharmaceuticals Reports Second Quarter 2013 Financial Results
REDWOOD CITY, Calif., Aug. 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the three and six months ended June 30, 2013. "With the successful completion of our Zalviso™ clinical program that includes data from all three Phase 3 studies, each of which met its primary e... 
Printer Friendly Version
08/05/13AcelRx Pharmaceuticals to Present at Canaccord Genuity 33rd Annual Growth Conference
REDWOOD CITY, Calif., Aug. 5, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the Canaccord Genuity 33rd Annual Growth Conference at the Intercontinental Boston, Boston, MA.  The presentation is scheduled for Thursday, August 15, 201... 
Printer Friendly Version
08/02/13AcelRx Pharmaceuticals to Hold Second Quarter 2013 Financial Results Conference Call and Webcast on August 12, 2013
REDWOOD CITY, Calif., Aug. 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release second quarter 2013 financial results after market close on Monday, August 12, 2013.  AcelRx management will host an investment-community conference call at 4:30 p.m. eastern time (1:30 p.m. pacific time) on A... 
Printer Friendly Version
07/23/13AcelRx Pharmaceuticals Announces Closing Of Public Offering And Exercise Of Option To Purchase Additional Shares
REDWOOD CITY, Calif., July 23, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), today announced the closing of the public offering of 4,370,000 shares of common stock, including 570,000 shares of common stock which were issued pursuant to the exercise of the underwriters' option to purchase additional shares, at a price of $11.65 per share to the public. The total gross proceeds of this offering were approximately $50.9 million with estimated net proceeds to AcelRx of $47.9 mill... 
Printer Friendly Version
07/18/13AcelRx Pharmaceuticals Announces Pricing of Public Offering of Common Stock
REDWOOD CITY, Calif., July 18, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced the pricing of its previously announced underwritten public offering of 3.8 million shares of its common stock, offered at a price of $11.65 per share to the public. The gross proceeds to AcelRx from this offering are expected to be approximately $44.27 million, before deducting underwriting discounts and commissions, and other estimated offering expenses payable by AcelRx.  All of the... 
Printer Friendly Version
07/17/13AcelRx Pharmaceuticals Announces Proposed Public Offering Of Common Stock
REDWOOD CITY, Calif., July 17, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) today announced that it intends to offer and sell shares of its common stock in an underwritten public offering. The Company expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of common stock offered in the public offering.  The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be co... 
Printer Friendly Version
07/02/13AcelRx Pharmaceuticals Joins Russell Global and Russell 3000 Indexes
REDWOOD CITY, Calif., July 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, has joined the broad-market Russell 3000® Index and the Russell Global® Index according to the final membership lists posted July 1, 2013. Annual reconstitution of Russell's U.S. indexes captures the 4,000 largest U.S. stocks as of the end of... 
Printer Friendly Version
07/01/13AcelRx Pharmaceuticals to Participate in Two Upcoming Investor Events
REDWOOD CITY, Calif., July 1, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that on July 9, 2013 the Company will participate in the Piper Jaffray Catalyst Symposium in Boston MA and on July 10, 2013, Richard King, President and CEO, will present a corporate overview at the JMP Securities Healthcare Confe... 
Printer Friendly Version
06/21/13AcelRx Pharmaceuticals to Host Investor Day on June 27, 2013
REDWOOD CITY, Calif., June 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, will host an Investor Day on Thursday, June 27, 2013, from 9:00 a.m. to 11:00 a.m. EDT (6:00 a.m. to 8:00 a.m. PDT) at the 21 Club, 21 West 53rd Street, New York, NY. Members of the AcelRx management team will present insights on the Company... 
Printer Friendly Version
05/29/13AcelRx Pharmaceuticals to Present at the Jefferies 2013 Global Healthcare
REDWOOD CITY, Calif., May 29, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the Jefferies 2013 Global Healthcare Conference at the Grand Hyatt, New York in New York, NY.  The presentation is scheduled for Tuesday, June 4, 2013 at 1... 
Printer Friendly Version
05/21/13Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
- Following major orthopedic surgery, Sufentanil NanoTab-treated patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p<0.001) - - Results confirm all previously reported Phase 3 trial outcomes, supporting submission of an NDA anticipated for third quarter 2013 - - AcelRx to conduct conference call and webcast today, May 21, 8:30 a.m. EDT (5:30 a.m. PDT) - REDWOOD CITY, Calif., May 21, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc... 
Printer Friendly Version
05/16/13AcelRx Pharmaceuticals to Present at the UBS Global Healthcare Conference
REDWOOD CITY, Calif., May 16, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that Richard King, President and CEO, will present a corporate overview at the UBS Global Healthcare Conference at the Sheraton New York Hotel in New York, NY.  The presentation is scheduled for Wednesday, May 22, 2013 at 9:30 a.m... 
Printer Friendly Version
05/08/13AcelRx Pharmaceuticals Reports First Quarter 2013 Financial Results
REDWOOD CITY, Calif., May 8, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the first quarter ended March 31, 2013. "We continue to make progress in clinical development of our product candidates.  We presented additional data at the recent American Society of Regional A... 
Printer Friendly Version
05/03/13AcelRx Pharmaceuticals to Hold First Quarter 2013 Financial Results Conference Call and Webcast on May 8, 2013
REDWOOD CITY, Calif., May 3, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release first quarter 2013 financial results after market close on Wednesday, May 8, 2013.  AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) on May ... 
Printer Friendly Version
05/02/13AcelRx Pharmaceuticals Presents Positive Clinical Data for the Sufentanil NanoTab PCA System at ASRA Medical Meeting
- Additional Phase 3 analysis show significantly faster reduction in pain and fewer patients with oxygen desaturation events for Sufentanil NanoTab PCA System than IV PCA with morphine - - Sufentanil NanoTab PCA System remains on track for a Q3 2013 NDA submission - REDWOOD CITY, Calif., May 2, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative thera... 
Printer Friendly Version
04/24/13Top-line Data Show AcelRx Pharmaceuticals' ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
- Patients in the 30 mcg sufentanil NanoTab treatment group experienced significantly greater reduction in pain as measured by SPID-12 vs. placebo - - ARX-04 is a rapid-onset, non-invasive investigational pain medication being evaluated for the short-term treatment of acute moderate-to-severe pain in a range of ambulatory care environments - REDWOOD CITY, Calif., April 24, 2013 /PRNewswire/ --- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the d... 
Printer Friendly Version
03/12/13AcelRx Pharmaceuticals Reports Fourth Quarter and Full-Year 2012 Financial Results
REDWOOD CITY, Calif., March 12, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), ("AcelRx"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today reported financial results for the fourth quarter and year ended December 31, 2012, and provided a corporate update. (Logo: http://photos.prnewswire.com/prnh/20130226/MM67303LOGO) "We made important strides in the ad... 
Printer Friendly Version
03/07/13AcelRx Pharmaceuticals to Hold Fourth Quarter 2012 Financial Results Conference Call and Webcast on March 12, 2013
REDWOOD CITY, Calif., March 7, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that it will release fourth quarter 2012 financial results after market close on Tuesday, March 12, 2013.  AcelRx management will host an investment-community conference call at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) o... 
Printer Friendly Version
03/04/13AcelRx Top-line Data Show Primary Endpoint Achieved in Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Post-Operative Pain in Major Open Abdominal Surgery Patients
- Patients experienced significantly greater reduction in pain as measured by SPID-48 vs. placebo (p=0.001) - - Adverse events in sufentanil-treated patients similar to placebo - - AcelRx to conduct conference call and webcast tomorrow, March 5, at 8:30 a.m. EST (5:30 a.m. PST) to discuss top-line results - REDWOOD CITY, Calif., March 4, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development a... 
Printer Friendly Version
02/27/13AcelRx Pharmaceuticals to Present at Two Upcoming Investor Conferences
REDWOOD CITY, Calif., Feb. 27, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that AcelRx will present a corporate overview at the following two investor conferences in March 2013: Cowen and Company 33rd Annual Health Care Conference Presenter: Richard King, President and CEO Date: Wednesday, March ... 
Printer Friendly Version
02/19/13AcelRx Pharmaceuticals Provides Clinical Trial Updates
Continued progress towards NDA submission for Sufentanil NanoTab PCA System in Q3 2013 REDWOOD CITY, Calif., Feb. 19, 2013 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced continuing progress on its two remaining Phase 3 trials of the Sufentanil NanoTab PCA System being studied in post-operative pain.  The fir... 
Printer Friendly Version
02/12/13AcelRx Appoints Adrian Adams to Board of Directors as Chairman
REDWOOD CITY, Calif., Feb. 12, 2013 /PRNewswire via COMTEX/ --AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced the appointment of Adrian Adams, Chief Executive Officer and President of Auxilium Pharmaceuticals, Inc., to its Board of Directors (Board) as Chairman of the Board. Thomas Schreck, co-founder of AcelRx and Board membe... 
Printer Friendly Version